Of note, in the subgroup analysis, the OS benefit from immunotherapy versus chemotherapy was significantly higher in patients with positive [defined as combined positive score (CPS) of positive tumor and ICs/total tumor cells ≥1%] or high (with a CPS ≥ 10%) PD-L1 tumors, but not in those with negative or low (CPS ≤ 10%) PD-L1 tumors.9 This evidence concerns the gene CD274 and neoplasm.